Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Poliomyelitis Overview 9 Therapeutics Development 10 Pipeline Products for Poliomyelitis - Overview 10 Pipeline Products for Poliomyelitis - Comparative Analysis 11 Poliomyelitis - Therapeutics under Development by Companies 12 Poliomyelitis - Therapeutics under Investigation by Universities/Institutes 14 Poliomyelitis - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Poliomyelitis - Products under Development by Companies 18 Poliomyelitis - Products under Investigation by Universities/Institutes 19 Poliomyelitis - Companies Involved in Therapeutics Development 20 Beijing Minhai Biotechnology Co., Ltd 20 Beijing Tiantan Biological Products Co., Ltd. 21 Bharat Biotech International Limited 22 Bilthoven Biologicals B.V. 23 Biological E. Limited 24 Boryung Pharmaceutical Co., Ltd. 25 Codagenix, Inc. 26 Daiichi Sankyo Company, Limited 27 Grifols, S.A. 28 Johnson & Johnson 29 LG Life Science LTD. 30 Nanolek, LLC 31 Panacea Biotec Limited 32 Sanofi Pasteur SA 33 Sentinext Therapeutics Sdn Bhd 34 Sinovac Biotech Ltd. 35 Taiga Biotechnologies, Inc. 36 Poliomyelitis - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Combination Products 38 Assessment by Target 39 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 45 (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole-cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 (diphtheria + pertussis (acellular) + poliovirus + tetanus) vaccine - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 immune globulin (human) - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 ImmunoRx - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 IPVGVI-3000 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 LBVC - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 LBVD - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 polio (monovalent) vaccine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 polio (virus like particle, bivalent) vaccine - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 polio [serotype sabin 1, 3] (bivalent) vaccine - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 polio [serotypes 1, 2, 3] (monovalent) vaccine - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 polio [strain Sabin] vaccine - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 polio vaccine - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 polio vaccine - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 polio vaccine - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 polio vaccine - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 polio vaccine - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 polio vaccine 2 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 poliomyelitis vaccine - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 VN-0105 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Poliomyelitis - Recent Pipeline Updates 73 Poliomyelitis - Dormant Projects 74 Poliomyelitis - Discontinued Products 75 Poliomyelitis - Product Development Milestones 76 Featured News & Press Releases 76 Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine 76 Mar 03, 2014: Inactivated Polio Vaccines Broadly Available for the World's Children in the Drive Toward Polio Eradication 77 Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 77 Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 78 Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 78 Appendix 80 Methodology 80 Coverage 80 Secondary Research 80 Primary Research 80 Expert Panel Validation 80 Contact Us 80 Disclaimer 81

Beijing Minhai Biotechnology Co., Ltd Beijing Tiantan Biological Products Co., Ltd. Bharat Biotech International Limited Bilthoven Biologicals B.V. Biological E. Limited Boryung Pharmaceutical Co., Ltd. Codagenix, Inc. Daiichi Sankyo Company, Limited Grifols, S.A. Johnson & Johnson LG Life Science LTD. Nanolek, LLC Panacea Biotec Limited Sanofi Pasteur SA Sentinext Therapeutics Sdn Bhd Sinovac Biotech Ltd. Taiga Biotechnologies, Inc.